Evaluation of blood-brain barrier penetration and examination of binding to human serum albumin of 7-O-arylpiperazinylcoumarins as potential antipsychotic agents by Żołek, Teresa et al.
 1
Evaluation of blood-brain barrier penetration and examination of 
binding to human serum albumin of 7-O-
arylpiperazinylcoumarins as potential antipsychotic agents 
Teresa Żołek,1* Orsolya Dömötör,2 Kinga Ostrowska,1 Éva A. Enyedy2 and Dorota 
Maciejewska1* 
1 Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Warsaw, 
Banacha 1, 02-097 Warsaw, Poland 
2 Department of Inorganic and Analytical Chemistry, University of Szeged, Dóm tér 7. H-
6720 Szeged, Hungary 
 
ABSTRACT 
The delivery of drugs to the brain is complicated by the multiple factors including low blood–
brain barrier (BBB) passive permeability, active BBB efflux systems, and plasma protein 
binding. Thus, a detailed understanding of the transport of the new potent substances through 
the membranes is vitally important and their physico-chemical characteristics should be 
analyzed at first. This work presents an evaluation of drug likeness of eight 7-O-
arylpiperazinylcoumarin derivatives with high affinity towards serotoninergic receptors 5-
HT1A and 5-HT2A with particular analysis of the requirements for the CNS chemotherapeutics. 
The binding constants to human serum albumin (HSA) were determined at physiological pH 
using fluorescence spectroscopy, and then their mode of action was explained by analysis of 
theoretical HSA complexes. Dynamic simulation of systems allowed for reliable evaluation of 
the interaction strength. The analyzed coumarins were able to pass BBB, and they present 
good drug likeness properties. They showed high affinities to HSA (log KQ = 5.3 – 6.0 which 
corresponds to -8.12 – -7.15 kcal mol-1 of Gibbs free energy). The changes of the emission 
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intensity upon binding to HSA were scrutinized showing the different mode of action for 4-
phenylpiperazinylcoumarins. The values of computed Gibbs free energy and determined on 
the basis of experimentally obtained binding constants log KQ coincide suggesting a good 
quality of the theoretical model. Overall the 8-acetyl-7-O-arylpiperazinyl-4-methylcoumarin 
derivatives represent valuable lead compounds to be further tested in various preclinical 
assays as a possible chemotherapeutics against CNS diseases. Studied coumarins can be 
metabolized by cytochrome P450 to aldehydes and hydroxy derivatives. The existence of 
other binding sites inside HSA than Sudlow’s site 1 was postulated. The longer aliphatic 
linker between coumarin and piperazine moieties favored binding to HSA in other than 
Sudlow site 1 pocket. 
KEYWORDS 7-O-arylpiperazinylcoumarins, blood–brain barrier permeability, molecular 
modelling, human serum albumin binding, spectrofluorometric. 
1. Introduction  
The main challenge during the development of new medicinal substances which target the 
central nervous system (CNS) is to ensure that the substance is present at the pharmacological 
target site at sufficient concentration in order to demonstrate clinical efficacy [1]. Although 
the strong binding of a drug molecule to its intended target is crucial for the strength of action, 
poor membrane permeability could result in a lack of in vivo efficacy. Thus, a detailed 
understanding of the transport of the substance through the membranes is vitally important for 
pharmacokinetic analysis and for a successful drug development. Drugs that specifically 
target the CNS must pass three major central barriers: the blood-brain barrier (BBB) formed 
by capillary endothelial cells, the blood-cerebrospinal fluid barrier (CSFB) formed by choroid 
plexus epithelia, and the third barrier formed by tightly connected arachnoid epithelium. The 
absence of the intercellular pores in the endothelial barrier in the brain means that molecules 
gain access to brain interstitial fluid by the lipid-mediated free diffusion or the carrier – or 
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receptor-mediated transport. The BBB is the most important barrier in the brain [2], that 
separates the brain from the rest of the body extracellular fluids and thereby protects it from 
potentially toxic substances in the bloodstream, as well as enables the cerebrospinal fluid of 
the brain to be precisely controlled [3]. Drug distribution into the cerebrospinal fluid (CSF) 
cannot be an indicator of BBB transport. CSF is in rapid equilibrium with the blood by 
convection, and the substances injected into the CSF diffuse quickly to blood, and poorly to 
the brain. The BBB function is enhanced by the high level of efflux transporters especially P-
glycoprotein (P-gp). Strong junctions of ions and small hydrophilic molecules to P-gp reduce 
permeation of such solutes [4], closing any paracellular pathway [5]. Consequently, the brain-
to-blood efflux systems, plasma protein binding, enzymatic activity, and cerebral blood flow 
can greatly alter the amount of the substance crossing the BBB. Only unionized, lipophilic 
and low molecular weight compounds can diffuse freely through the endothelial membrane 
and may passively cross the BBB if they do not bind to the efflux transporters located in the 
brain capillaries of endothelial cells. Small ions and polar molecules cannot cross this barrier 
[6, 7]. 
Many coumarins and their derivatives underwent extensive investigations aimed to 
assess their beneficial effects on human health [8-10]. It has been shown, that they impact the 
CNS based on dopaminergic and serotonergic affinities, interactions with benzodiazepine 
receptors, and/or inhibition of cholinesterase and monoamine oxidases [11]. Among different 
pharmacological properties, their strong binding with the CNS receptors appears to be a very 
important biochemical feature, and thus coumarins can be a valuable resource of 
chemotherapeutics for the treatment of CNS diseases. Many scientific groups search for the 
new antipsychotic drugs among coumarin derivatives, based on their affinities to serotonergic 
receptors 5-HT1A and 5-HT2A [12-14]. It was found that activities of coumarin analogs can be 
modulated via their molecular architecture. For example, it was shown that the presence of 
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bulky aliphatic chain like a sec-butyl group at C-8 position decreased the antipsychotic 
activity, but the substitution of the methoxy group at C-3 position is favorable for their 
pharmacologic potential [15]. It was also observed that compounds with the N-arylpiperazine 
fragment and the methyl groups at C-3 and/or C-4 positions of the coumarin ring were the 
most promising ones in various biological tests [13]. 
Human serum albumin (HSA), one of the main carrier proteins plays an important role 
in the transport and disposition of exogenous and endogenous compounds present in the blood 
[16]. It is known that distribution in the body and pharmacological effect of 
chemotherapeutics are both correlated with the nature and magnitude of drug-HSA 
interactions. Although bound and unbound drug concentrations are predominantly in 
equilibrium, problems might occur if the HSA affinity of a drug is extremely high. Weak 
plasma protein binding leads to a short lifetime and/or poor tissue distribution of the drug and 
other organic compounds, whereas strong binding decreases the concentrations of free drugs 
in plasma [17]. The specific physiological activity of the aromatic and heterocyclic ligands 
upon adduct formation with serum albumin originates from the presence of two hydrophobic 
pockets in subdomains IIA (Sudlow site 1) and IIIA (Sudlow site 2) of HSA [18]. HSA 
contains a single intrinsic tryptophan residue at position 214 in domain IIA, where a large 
hydrophobic cavity is present, and its fluorescence is sensitive to the ligands bound nearby 
[19]. Therefore, information about the HSA-ligand binding can be obtained by the 
measurement of intrinsic fluorescence intensity of the tryptophan residue before and after the 
addition of the tested compounds. HSA is a well-known transport peptide of numerous 
coumarin derivatives, especially for warfarin – an anticoagulant drug [20-23]. It has been 
reported that compounds with coumarin, chromone and chromanol rings can bind to HSA in 
subdomain IIA. Elimination of the 4-hydroxy group decreased the binding affinity in this 
series of compounds, and pyranone in not a ligand to HSA [24]. It was also shown that the 
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acetyl group at C-8 position significantly decreased HSA binding but its role in the ligand-
protein interactions was not explained definitely [25]. Therefore, additional information 
concerning the structural features which favor HSA binding for very potent substances 
evaluated in vitro assays is of high demand in the course of drug search. The analysis of 
potential drug binding to plasma protein is interesting because the unbound drug fraction 
affects many pharmacokinetic parameters as the steady-state distribution volume, but also it 
provides useful information for the design of the administration regimen dose. 
In the present study, we selected eight compounds (1a – 4a, 1b – 4b) synthesized in our 
research group which belongs to the 8-acetyl-7-hydroxy-4-methylcoumarin family connected 
with the N-arylpiperazine substituent via propyloxy or butyloxy linkers (Fig. 1). These 
coumarin derivatives showed very high affinities to 5-HT1A by in vitro assays (IC50 within 
range 0.8 – 2.2 nM) and high affinities to 5-HT2A (8 – 138 nM) receptors [26], which are the 
initial factors in the selection of compounds to the next step in the pipeline of drug discovery 
which targets CNS. Before in vivo tests, the most favorable strategy is to calculate the most 
important drug likeness parameters, with special emphasis on the requirements of the CNS 
drugs. As a result, we evaluated ADME parameters based on the chemical structures for our 
set of derivatives to estimate their propensities cross BBB, as well as evaluating their 
toxicities. The interaction between coumarin derivatives and HSA was measured during blood 
transportation process in vitro under physiological conditions by fluorescence spectroscopy 
and was simulated by molecular docking and molecular dynamics (MD) methodology. We 
believe that this study provides basic data for clarifying the in vivo binding mechanisms of 
coumarin derivatives with human serum albumin. 
2. Materials and Methods 
2.1. Theoretical methodology 
2.1.1. Chemical structures of tested coumarins and HSA 
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Eight compounds were selected and studied (Fig. 1): 1a (8-acetyl-7-{3-[4-(2-
fluorophenyl)piperazin-1-yl]propoxy}-4-methylchromen-2-one), 2a (8-acetyl-7-{3-[4-(3-
methoxyphenyl)piperazin-1-yl]propoxy}-4-methylchromen-2-one), 3a (8-acetyl-7-{3-[4-(2-
cyanophenyl)piperazin-1-yl]propoxy}-4-methylchromen-2-one), 4a (8-acetyl-7-{3-[4-(2,3-
dichlorophenyl)piperazin-1-yl]propoxy}-4-methylchromen-2-one), 1b (8-acetyl-7-{4-[4-(2-
fluorophenyl)piperazin-1-yl]butoxy}-4-methylchromen-2-one), 2b (8-acetyl-7-{4-[4-(3-
methoxyphenyl)piperazin-1-yl]butoxy}-4-methylchromen-2-one), 3b (8-acetyl-7-{4-[4-(2-
cyanophenyl)piperazin-1-yl]butoxy}-4-methylchromen-2-one), and 4b (8-acetyl-7-{4-[4-(2,3-
dichlorophenyl)piperazin-1-yl]butoxy}-4-methylchromen-2-one). They belong to two groups 
of coumarin derivatives, which differ in the length of the linker between two rings: the 
coumarin and the piperidine. Namely, compounds 1a – 4a are composed with propylene but 
compounds 1b – 4b with a butylene linker. Coumarin derivatives are poorly soluble in water 
so prior biological tests they were transformed into hydrochlorides to increase their solubility. 
In each case, the cations were used in the theoretical studies, and the site of protonation was 
proposed. The starting structures of the coumarin derivatives were constructed by Discovery 
Studio 2017R2 visual interface BIOVIA [27]. The geometries of all compounds were 
optimized using the density functional theory (DFT) with the B3LYP/6-311G (d,p) hybrid 
functional as implemented in Gaussian 09 [28]. The known crystal structure of HSA (PDB 
ID: 2BXD), which included a warfarin ligand in active site was obtained from the RCSB 
Protein Data Bank. Ligand, water molecules, and inorganic ions were removed, hydrogen 
atoms were added, and the calculations were made at the physiological pH. 
2.1.2. Prediction of ADMET descriptors 
ADMET parameters were computed by applying ADMET PredictorTM version 8.5 
program [29] using qualitative and quantitative models. Various drug likeness parameters like 
Lipinski’s rule of five, the topological polar surface area (TPSA), the proton dissociation 
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constants (pKa), a Maximum Recommended Therapeutic Dose (MRTD), qualitative 
likelihood of penetrating the blood-brain barrier (BBB_filter) express as high/low, the 
logarithm of the blood-brain barrier partition coefficient logCbrain/Cblood (logBB), percentage 
of unbound drug to proteins within blood plasma (%Unbnd), blood-to-plasma concentration 
ratio (RBP = Cwhole-blood/Cplasma) and likelihood of the P-glycoprotein (P-gp) inhibition were 
estimated for all compounds at pH 7.4. Prediction of metabolic phase I indicators was made 
using cytochrome P450 (CYP 450) forms CYP 1A2, 2C9, 2C19, 2D6 and 3A4. All the CYP-
metabolites generated for each compound were evaluated for risk potential whenever it was 
possible. Phase II metabolism of coumarin derivatives was investigated to determine the 
probability whether human uridine 5’-diphosphate-glucuronosyltransferases (UGT) can be 
involved. Hepatotoxicity parameters were specifically studied using relevant biomarkers: 
alkaline phosphatase (AlkPhos), serum glutamate oxaloacetate transaminase (SGOT/AST), 
serum glutamate pyruvate transaminase (SGPT/ALT), -glutamyl transferase (GGT) and 
lactate dehydrogenase (LDH). 
2.1.3. Starting structures of ligands by molecular docking simulations 
The molecular docking experiments were carried out using the Lamarckian Genetic 
Algorithm (LGA) implemented in the AutoDock 4.2.3 program [30]. HSA was held rigid, all 
torsion bonds of the ligands were considered as free, and there was no consideration regarding 
the effect of solvent on the interactions. The protein input files were prepared for docking by 
adding Gasteiger charges on atoms. Based on the site-specific markers used in our 
experiment, the coumarins were docked to the Sudlow site 1. The size of the grid box was 
defined in the shape of a three-dimensional grid (50  50  50 Å) at a resolution of 0.375 Å. 
The docking parameters used were as follows: GA population size: 150 and the maximum 
number of energy evaluations: 250 000. During docking, a maximum number of top 30 
conformers was considered, and the root means square (RMS) cluster tolerance was set to 2 
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Å. The conformers corresponding to the lowest free energy were used as the starting points in 
the MD simulations. 
2.1.4. HSA-ligand complexes by molecular dynamics simulations 
MD simulations of the ligand-HSA complexes were performed in solution to better 
reflect experimental systems and the intermolecular interactions which play a crucial role in 
their stability. We used the CHARMm force field [31] implemented in the module of 
Discovery Studio 2017R2. Each protein-ligand complex was immersed in a cubic box of 
TIP3P water molecules [32] (12 Å from the solute surface) and neutralized by the addition of 
chloride anions. The MD strategy consisted of two-step energy minimization of the solvated 
complexes. First of all, the water molecules were optimized using the steepest descent method 
with 1000 steps, and then the conjugate gradient method was employed for another 1000 steps 
while protein and ligand were kept frozen. The restraints were weak with force constant of 10 
kcal mol-1 Å-2. Secondly, using the same approach in the first step above was performed with 
all atoms relaxed. The MD protocol contained a heating step performed for 50 ps up to 300 K. 
Before proceeding to production, MD step equilibration was done at 300 K for 50 ps. In the 
stages of heating and equilibration, the solutes (protein and ligand) were fixed with force 
constant of 2 kcal mol-1 Å-2. The equilibrated system was taken as the starting structure for 
production runs using two phases. In the first phase, NVT was performed at 300 K for 200 ps 
in the presence of a weak harmonic restraint on the solute, and in the second phase NPT at 
300 K and 1 bar for 5 ns. The periodic boundary conditions were used and the motion 
equations were integrated by applying the Leapfrog Verlet algorithm [33] with a time step of 
2 fs. The trajectories were recorded at 10 ps interval. 
2.1.5. Binding free enthalpy calculations using MM-PBSA 
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The free enthalpy calculations were carried out using the MM-PBSA approach [34] 
embedded in Discovery Studio 2017R2. The atomic coordinates of HSA and each ligand were 
extracted from a single trajectory of the MD simulations obtained using explicit water 
molecules. Each binding free enthalpy was calculated based on the average structures 
obtained from the last 2 ns of MD trajectories. The components of each complex were 
minimized using the conjugate gradient method for 10 000 steps after 100 steps of the 
steepest descent algorithm and a dielectric constant of 4 for the electrostatic interactions until 
the RMS gradient of the structure was less than 0.001 kcal mol-1 Å-1. The binding free 
enthalpy (Gbind) between a ligand and a protein was estimated given the functional form of 
MM-PBSA formalism in Eq. 1.  
Gbind = GHSA-ligand – (GHSA  + Gligand)    (1) 
where GHSA-ligand is free enthalpy of complex, GHSA is free enthalpy of HSA and Gligand is free 
enthalpy coumarin derivative. 
2.2. Experimental methodology 
The lipophilicities and the dissociation constants for coumarin derivatives together with 
equilibrium constants for HSA-ligand complexes were determined experimentally. 
2.2.1. Preparation of stock solutions of HSA and coumarins 
HSA (with fatty acids as lyophilized powder), KOH, HCl, KCl and all buffer 
components used for lipophilicity measurements are Sigma-Aldrich products in puriss quality. 
Milli-Q ultrapure water was used as a solvent of the samples and stock solutions. HSA 
solution was prepared in phosphate buffer (20 mM, pH 7.40) containing 0.1 M KCl strictly on 
the same day as the experiment was done. Estimated concentration of HSA stock solutions 
was calculated from its UV absorption: e280 nm(HSA) = 36850 M
−1 cm−1 [35]. Hydrochloride 
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salts of the coumarin derivatives were dissolved in slightly acidic water (pH ~ 4) at 100 µM 
concentration. 
2.2.2. Estimation of pH-dependent lipophilicity and proton dissociation constants 
(pKa) for coumarins 
Distribution coefficient (DpH) values of the compounds were determined by the 
traditional shake-flask method in n-octanol/buffered aqueous solution at various pH values at 
25.0 ± 0.2 °C. pH values of the samples were adjusted with n-octanol pre-saturated aqueous 
solutions containing different buffer systems at ca. 50 mM concentration and 0.10 M KCl. 
Applied pH values are follows: pH = 2.01 (H3PO4/NaH2PO4); pH = 3.01 (formic acid/Na-
formate); pH 4.01 (formic acid/Na-formate); pH 5.01 (acetic acid/Na-acetate); pH 5.41 (2-(N-
morpholino)ethanesulfonic acid (MES)/its Na-salt); pH 6.03 (MES/its Na-salt); pH 6.53 
(MES/its Na-salt); pH 7.04 (NaH2PO4/Na2HPO4); pH 7.50 (NaH2PO4/Na2HPO4); pH 8.45 
(NH4Cl/NH3); pH 8.97 (NH4Cl/NH3); pH 10.30 (3-(cyclohexylamino)-1-propanesulfonic acid 
(CAPS)/its Na salt). Compounds were dissolved in slightly acidic n-octanol pre-saturated 
water (pH ~ 4, I = 0.10 M KCl) and aliquots were mixed with the certain buffer systems in 1:2 
volume ratio in order to get the stock solutions. Final compound concentration was 5 − 40 
µM, and exact pH values were measured with an Orion 710A pH-meter equipped with a 
Metrohm combined electrode (type 6.0234.100) after three-point calibration of the electrode 
system. Stock solutions and water presaturated n-octanol were gently mixed in 1:1, 1:0.02 or 
1:0.01 volume ratio with Heidolph Reax 2 overhead shaker (~20 revolutions per minute 
(rpm)) for 2h. The mixtures were centrifuged with Eppendorf MiniSpin Plus centrifuge (5000 
rpm, 3 min). After phase separation, UV−visible (UV−vis) spectrum of the compound in the 
aqueous phase was compared to that of the original stock solutions and DpH values of the 
compounds were calculated according to the following equation (Eq. 2): 
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DpH =  
Abs (stock. sol.)
Abs (aqueous phase af ter separation)
-1  ×
V (aqueous phase)
 
	( -octanol)
  (2) 
A Thermo Scientific Evolution spectrophotometer and a Hewlett Packard 8452A diode array 
spectrophotometer were used to measure the UV-vis spectra in the interval 200–500 nm. 
pH dependence of the DpH values were utilized to estimate proton dissociation 
constants (pKa) of 1a – 4a and 1b – 4b. According to our model both protonated (HL
+) and 
charge neutral (L) species distribute between the polar and non-polar solvent phases, namely 
both PHL+ and PL constants can be derived from the measurements since DpH value is equal to 
the corresponding partition coefficient (P) value in that pH range where the compound is 
presented practically in one single protonation state (either HL+ or L). The pKa values were 
calculated according to Eq. (3): 
Ka =	
 P
HL+
 - DpH   ×  H
+ 
 DpH	- PL 
    (3) 
where [H+] is the free proton concentration in aqueous phase calculated from the measured 
pH. The pKa values were fitted with the computer program PSEQUAD [36] using the pH – 
DpH data pairs and PHL+, PL constants. A more detailed description of lipophilicity models and 
model selection can be found in the Supplementary Materials. 
2.2.3. Spectrofluorometric measurements of interaction with HSA 
Phosphate buffer (20 mM, pH 7.4) with 0.10 M KCl was used for sample preparation; 
spectra were recorded after 10 min incubation. Two kinds of experiments were carried out: 1 
µM HSA and various amounts of coumarin compound (from 0 to 25 eq.) were used for 
quenching experiments; and intrinsic fluorescence of the compounds was examined in 
samples containing 2.4 – 3.3 mM compound and 0 – 23 mM HSA. The excitation wavelength 
was chosen for 295 nm in quenching experiments; the emission intensities were read in the 
range of 310 – 500 nm with 5 nm/5 nm slit widths. In the second experiment, compounds 
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were excited at 330 nm; the emission was recorded in the range of 340 – 550 nm with slit 
widths of 10 nm/10 nm. Spectra were corrected by the light scattering effect of HSA 
appearing at these conditions. Computer program PSEQUAD was utilized for calculation of 
equilibrium constants for HSA − ligand complexes from both types of experiments as 
described in our former work [37]. 
Three-dimensional fluorescence spectra were obtained between 230 – 400 nm 
excitation and 250 – 550 nm emission wavelengths with slit widths of 5 nm/5 nm. Corrections 
for self-absorbance and inner filter effect were necessary since the exciting and emitted light 
were partly absorbed by the compounds. The following formula (Eq. 4) was used for spectral 
correction: 
Fcorrected = 	Fmeasured × 10
 A(EX) + A(EM) 
2    (4) 
where corrected fluorescence (Fcorrected) is given as the product of the measured intensity 
(Fmeasured) and 10 to the power of average absorbances measured at the excitation (A(EX)) and 
emission wavelengths (A(EM)). 
3. Results and discussion  
3.1. Assessing of ADMET parameters 
3.1.1. Blood-brain barrier in silico assay 
The physico-chemical parameters with relation to Lipinski´s rule of five are presented in 
the Supplementary Material, Table S1 for 1a – 4a and 1b – 4b. As can be seen the tested 
coumarins fulfill the majority of basic requirements for orally administrated drugs. Only the 
values of molecular weight (MWt) and log D are fairly high for 4b with the two chlorine 
substituents. Since these parameters should be in specific range for substances aimed at the 
CNS their values were scrutinized below together with the following parameters being crucial 
for evaluation of BBB penetration which are shown in Table 1. The topological polar surface 
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area (TPSA) is a key parameter for prediction of CNS penetration. TPSA was suggested to be 
a measure of a molecule’s hydrogen bonding and its value should not exceed certain limit 
lower than for other drug’s classes [38, 39]. Two limits were proposed, namely a lower limit 
of 60 – 70 Å2 and a higher limit of 90 Å2 [40-42]. TPSA values of all compounds in our study 
are in these ranges which creates basic conditions for the penetration BBB. MWt is an 
important parameter determining the lipid-mediated free diffusion of molecules across the 
BBB. Small molecules may cross the BBB due to their MWt lower than 400 – 500 g mol-1, 
however, according to the suggestion of van de Waterbeemd et al. [43], MWt should be below 
450 g mol-1 or even below 400 g mol-1 [44], because the BBB is a specialized structure 
between the cerebral capillaries and the brain parenchyma. Only 1a and 3a, reported herein, 
have MWts ≤ 450, but 2a, 1b and 3b show values close to 450 g mol-1. Nevertheless, larger 
molecules can be transported by receptor- or transporter-mediated systems. Another important 
drug property that governs permeation across the CNS tissue barrier is the molecular 
lipophilicity, expressed as log P, where P is the partition coefficient. Capillaries of the brain 
are devoid of aqueous pores which facilitate aqueous diffusion, thus lipid diffusion becomes a 
critical determinant of BBB drug penetration, and a higher lipophilicity is required to achieve 
greater CNS efficacy. On the other hand, the more lipophilic compounds frequently 
demonstrate a higher level of binding to serum proteins. From the other side, the lowest log P 
values of ∼2 were suggested to be the most optimal to minimize the metabolism and toxic 
side effects. Thus, lipophilicity and protein binding can be considered as conflicting 
characteristics in regard to CNS penetration. The BBB penetration was optimal for several 
classes of CNS active substances when log P values were in the range of 2 – 5 [45, 46]. The 
log P values for tested coumarins were in the range 3.41 – 4.98 close to that of marketed CNS 
drugs. The logarithm of the distribution coefficient (log D), which characterized ionic 
substances, needs to be greater than 0 and less than 4 for better brain permeation [43]. For 
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eight analyzed coumarins log D values are lower than log P values and fall within the range 
3.32 – 4.68. Only derivatives 4a and 4b with two Cl substituents show relatively high log D 
values, which indicates a higher probability of binding to plasma proteins. An important 
parameter is hydrogen bonding that occurs with the surrounding medium i.e. water. It has 
been reported that for a compound to be transported through the BBB, the H-bond donors 
should be  3 and H-bond acceptors should be  7 [47]. An inspection of the investigated 
coumarins H-bond donors and acceptors suggests that all have a potential to effectively cross 
the BBB. A specific attention was given to the proton dissociation constant (pKa). Fischer et 
al. [48], estimated pKa limit between 4 and 10 in a study of comparative properties for BBB 
penetration. The predicted pKa values of all compounds fall in the range of 6.74 – 7.41 (Table 
1) and the shortening the linker from the butylene to the propylene chain decreases the pKa 
values. The computed values are in good agreement with the experimental values (see Section 
3.2). 
On the basis of our findings, the calculated BBB permeation parameters as BBB_filter 
and blood-brain barrier partition coefficient logBB are promising for tested coumarins (Table 
1). BBB_filter is a qualitative likelihood of crossing the BBB and logBB is a measure of the 
partitioning between brain and blood tissue, quantified by the ratio of the solute 
concentrations in brain and blood. The BBB_filter parameter is indicated as high, and the 
values of logBB’s are found in the range from -0.610 to 0.368, that correlates with the 
permeation of high-to-moderate for all tested compounds. The logBB values for three 
compounds 1b, 4a and 4b, with halogen atoms were found to be close to 0.3 values, 
suggesting that this kind of substitution increases the potential of drugs for BBB penetration. 
Compounds 3a and 3b with cyano group have the lowest logBB values (close to -0.6) 
suggesting an unfavorable impact of cyano group on BBB crossing. 
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Yet another important property of a potential drug is its ability to bind to plasma 
proteins (HSA and 1-acid glycoprotein (AGP)), which is in most cases considered as 
undesirable. Depending on the drug and the target, high affinity to plasma proteins may 
consequently increase or decrease the efficacy of drug transport. A drug bound weaker can 
more efficiently traverse cell membranes or diffuse. The active efflux transporter at the BBB 
is P-glycoprotein (P-gp), which performs active back-transport of drugs from the brain to 
blood. A successful CNS drug should not be an efficient P-gp substrate (in vivo) and also 
possess low-affinity to serum albumin (KD < 10 mM) [49]. Three theoretical parameters 
characterize these properties: the percent of drug unbound to protein within blood plasma – 
%Unbnd, the concentration of the drug in whole blood compared to plasma – RBP, and the 
mode of the interaction with P-gp. For the analyzed coumarins the values of %Unbnd are in 
the region 0.997 – 2.347%, and the values of RBP in the region 0.604 – 0.667 (Table 1), what 
suggests that all compounds fall in the region of strong plasma protein binding. 
Emerging evidence has highlighted a potential role for the efflux transporter P-gp 
expressed at the BBB in the etiology of treatment-resistant depression [50, 51]. This 
neurological disorder can be improved by inhibiting drug efflux at the blood-brain barrier. In 
our study, 1a – 4a and 1b – 4b exert P-gp inhibition effects (Table 1) what suggests that those 
coumarins can suppress P-gp activity and can be considered as promising compounds for 
further development steps as novel therapeutic agents. 
3.1.2. Biotransformation of the tested coumarins 
The processes of drug biotransformation are the enzymatic conversions of the drugs to 
their metabolites which are classified as either phase I or phase II reactions based on the 
nature of the chemical modifications and the enzymes involved. The majority of phase I 
reactions are mediated by a large family of CYP450 enzymes, while phase II occurs 
predominantly by the UGT enzymes, distributed in various organs in human body. Modes of 
 16
action (inhibition/substrate) for different isoforms CYP450 are presented in Table 2. All 
studied coumarins are possible substrates for isoenzymes CYP1A2 and CYP2C19 and, on the 
other hand, are likely to inhibit CYP2C9. Compounds (3a and 3b) with (2-cyanophenyl) 
piperazinyl moiety cannot be metabolized by CYP2D6 isoform, while the other tested 
coumarins may be substrates and inhibitors to both CYP2D6 and CYP3A4. Hypothetical 
metabolites of tested coumarins are presented in Fig. S1 in Supplementary Materials. We can 
see those main metabolites are aldehydes (up to 64%) which are formed by breaking the C-N 
bond at the piperazine ring. The remaining metabolites are formed by hydroxylation of the 
benzene ring or the methyl group at C-4 atom in coumarin ring moiety. Additionally, nine 
main microsomal hepatic UGTs were examined to identify which isoforms may be 
responsible for coumarins glucuronidation reaction leading to their easier elimination. All 
coumarins are predicted to be substrate for only one isoenzyme 1A4, whereas none of them 
was predicted to be substrate for isoenzymes 1A1, 1A3, 1A6, 1A8, 1A9, 1A10, 2B7 and 2B15 
(see Table S2 in Supplementary Materials). 
3.1.3. Prediction of toxic effects 
The predicted values of toxicity parameter for coumarins 1a – 4a and 1b – 4b are 
shown in Table 3. Among these toxicity parameters, MRTD represents a qualitative 
assessment of maximum recommended therapeutic dose administrated orally. To develop an 
effective oral drug, the MRTD value should be greater than 3.16 (mg/kg-bw/day), which can 
indicate that the selected compound has fewer side effects. Compounds 2a, 2b, 4a, and 4b 
have MRTD value greater than 3.16, indicating that the appearance of side effects is less 
likely for these compounds. Among compounds with MRTD values below 3.16 (mg/kg-
bw/day) are derivatives with fluoro and cyano substituents. Further parameters are related to a 
liver toxicity. During a screening, all coumarin derivatives being predicted as “non-toxic” 
taking into account relevant biomarkers (AlkPhos, GGT, LDH, SGOT, and SGPT). 
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3.2. Proton dissociation equilibria and intrinsic fluorescence of the tested 
coumarins 
All investigated compounds have a poor aqueous solubility, accordingly UV-vis 
spectrophotometry, that requires lower concentrations, was used for first to monitor their 
proton dissociation processes at highly diluted concentrations (2 − 20 µM) in pure aqueous 
solution. Molar absorbance of the studied compounds at acidic conditions (pH = 2.5) ranges 
from ε = 11600 to 17100 M-1cm-1 with λmax = 321 – 322 nm (see Table 4). However, these 
intense ligand bands were found to be fairly insensitive to the (de)protonation of the 
molecules. Only compound 2a (see Fig. 2) shows the tendentious but weak spectral changes 
at pH between 5.0 and 8.5, and a pKa value of 7.06 ± 0.01 could be calculated for this process. 
The deprotonation constant most probably belongs to one of the piperazine nitrogens, i.e. to 
the proton dissociation of the +NH‒CH2 moiety. Since chromophore groups (coumarin and 
phenyl) are situated relatively far from this piperazine nitrogen, UV absorption spectra are 
nearly insensitive to the (de)protonation processes. 
In order to obtain information about the protonation equilibrium of the other compounds 
as well, pH-dependent lipophilicity studies were carried out. The strongly lipophilic nature of 
the studied compounds required modified experimental conditions, namely the water-to-
octanol volume ratio was changed in favor of the water (see details in the Section 2.2.2). Two 
models were considered for the calculations (see details in the Supplementary Materials, 
Section S-2). Figure 3 shows the n-octanol/water distribution coefficients (DpH) of 2a 
determined at different pH values. DpH values in Fig. 3 clearly reveal the distribution of the 
HL+ species between the n-octanol and the aqueous phase, since DpH values are larger than 
zero even at the lower pH range (when only HL+ species is present in the solution). Measured 
DpH values show a sigmoidal shape in dependence of the pH and the inflection point of this 
curve corresponds to the pKa of compound 2a, which was fitted with the computer program 
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PSEQUAD using the pH ‒ DpH data pairs. In contrasts to the most widely accepted model 
(model 1), where an only distribution of the neutral form is expected (dashed line in Fig. 3), 
our method operates with the partition of both protonation states (model 2). Obtained pKa, log 
PL and log PHL values are listed in Table 4. The lipophilicity of tested coumarins is within the 
limits for the drugs targeted CNS. The pKa values determined in aqueous solution are in the 
range of 6.35 ‒ 7.20. It is clear that displacement of the propylene linker between the 
piperazine and coumarin moieties to butylene linker tendentiously increases the log PL and 
pKa values. This phenomenon helped us to predict these constants for 4b (see Supplementary 
Materials, Section S-3, Fig. S3), that was found to be fairly insoluble in water at pH > 6.5. 
Chloride substitution of the compounds undoubtedly results in increased acidity due to its 
high electronegativity. Fluorine monosubstitution interestingly leads to a small increase in the 
pKa values compared to the methoxy derivatives, and nitrile substitution has only a minor 
effect on the acidity of the compound as well. Notably, the computed pKa values are in good 
agreement with the constants reported in our former work for their structural analogues 
containing the same 4-(4-phenylpiperazin-1-yl)propyloxy or -butyloxy group but in a 
different position on the coumarin ring. Furthermore, the experimental pKa values fit well to 
the predicted ones in the case of ligands 1a, 1b, 2a, 2b, 3a, and 3b, although they differ more 
significantly for the dichlorine substituted 4a and 4b. 
Species distribution was calculated at pH 7.4 based on the determined pKa values (Table 
4). All the studied coumarins are protonated partly at this particular pH, but 61 – 92% are 
present in the neutral (L) form. Distribution coefficients (D7.40) calculated for pH 7.4 reflect 
the highly lipophilic character of the predominant neutral forms, and even HL+ forms are still 
lipophilic according to the log PHL values determined. The fluorescent activity of the 
compounds is expected as they contain the coumarin moiety. Accordingly, their intrinsic 
fluorescence was examined and the position of emission maxima (l(EM)max) are collected in 
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Table 4. We have found that all compounds are weakly fluorescent and the actual protonation 
state of the molecules has no considerable effect on it. The characteristic high emission of 3-
methyl coumarins is most probably quenched by the acetyl substitution at position 8 on the 
coumarin ring [52]. The butoxy derivatives show somewhat higher fluorescence compared to 
their propoxy counterparts, 3a and 3b are the most emissive compounds. 
3.3. Interaction with HSA: spectrofluorometric studies 
The interaction of compounds 1a – 4a and 1b – 4b with human serum albumin (HSA) 
was investigated by fluorescence spectroscopy via the intrinsic fluorescence of the protein and 
the compounds as well. HSA, as the most abundant protein constituent of blood plasma, has 
outstanding capacity to transport a wide variety of endogenous compounds (e.g. fatty acids, 
bilirubin, steroids, and metal ions) and pharmaceutics. Its concentration in blood plasma is ca. 
630 mM [53, 54]. HSA comprises hydrophobic binding sites 1, 2 and 3 located in the 
hydrophobic pockets in subdomains IIA, IIIA and IB respectively. The only tryptophan 
(Trp214) residue in HSA is responsible for most of the intrinsic fluorescence of the protein 
and it is located near to site 1. Trp214 can be selectively excited at l = 295 nm and it shows 
strong fluorescence between 310 and 400 nm (with a maximum at 340 nm) that can be 
attenuated by a binding event at or close to Trp-214 owing to its susceptibility to changes in 
its environment [53-55]. Thus, direct studies on the binding at the primarily assumed binding 
pocket become possible. 
The HSA – compound interaction was revealed to be quite fast in time-dependence 
measurements (completed within few seconds, see Fig. S4 in Supplementary Materials), 
therefore 10 min incubation time was used to ensure the equilibrium state for the HSA 
binding experiments. A correction equation was used to reduce to significant self-absorption 
and inner filter effect of the compounds. Representative emission spectra are presented in Fig. 
4 for the 4a ‒ HSA system and in the Supplementary Materials, Fig S5 for the 1b ‒ HSA 
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system. As the studied compounds are fluorescent themselves, their intrinsic emission bands 
partly overlap with that of HSA. This phenomenon did not hinder the determination of 
quenching constant. The two calculation methods, namely when restricted wavelength range 
(310 – ca. 340 nm) was used and the emission originated from the ligand was eliminated or 
when all the three components (HSA, HSA – ligand and unbound ligand) were considered to 
be fluorescent provided similar quenching constants (log KQ) within a standard deviation of ± 
0.1. The computer program PSEQUAD was utilized to compute conditional stability constants 
(log KQ) which collected in Table 4. 
It is noteworthy that normalized quenching curves plotted against the ligand-to-HSA 
ratios shown in Fig. 5 do not tend to zero, this can be explained by the partial quenching of 
Trp-214 fluorescence. This phenomenon was taken into consideration in our calculations (see 
details in our former work [23]). According to Fig. 5 and to the calculated log KQ values in 
Table 4 the studied compounds show the different capability to quench the protein 
fluorescence. The emission intensity was practically unaltered in the case of 1b and 2b, 
consequently, no quenching constant could be computed; while remarkable binding of their 
propyloxy analogs 1a and 2a were revealed at site 1 (subdomain IIA). The log KQ values 
indicate a clear trend of the binding strength of the compounds at site 1 on HSA: 4a > 4b > 3a 
≥ 3b >> 2a > 1a. Notably, the differences between the values obtained for 4a, 4b, 3a, and 3b 
is relatively small. According to the fluorescence quenching measurements most compounds 
(except 1b and 2b) bind in a great manner on site 1, and all propoxy derivatives show a 
somewhat higher affinity towards this site compared to their butoxy pairs. The determined 
binding constants (log KQ = 5.3 – 6.0) are slightly higher on average compared to those of 
their close related analogs (log KQ = 4.8 – 5.8) reported in our former work [23], but 
significantly lower than that of some reduced Schiff base coumarin compounds examined 
formerly by some of us [56]. 
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As described in the former Section, the studied coumarin compounds are fluorescent 
themselves and the effect of albumin binding on their intrinsic fluorescence was also 
investigated. Three-dimensional fluorescence spectra recorded for 3a and/or HSA (Fig. 6) 
clearly show that the peak of the compound is increased moderately upon binding to the 
protein while the peak belonging to the HSA is quenched. Figure 7 shows the spectral and 
intensity changes of 3a in the presence of increasing amount of HSA and an unequivocal 
increase in the intensity and slight blue shift of λ(EM) can be seen. Similar behavior was found 
for the compounds 4a, 4b, 1b, and 2b also, confirming the sensitivity of their intrinsic 
fluorescence to binding to HSA. However, the latter ones responded with a decrease in their 
intensity upon binding to the protein (see Fig. S6 and S7 in Supplementary Materials). Based 
on the changes of the emission intensity binding constants could be also computed. Calculated 
log K = 5.73 ± 0.1 for the 3a ‒ HSA system corresponds well to the value determined in the 
quenching experiment (log KQ = 5.75 ± 0.1), which strongly supports that Sudlow site 1 
represents the only significant binding pocket for this compound. Noteworthy log K = 6.51 ± 
0.1 and 6.23 ± 0.1 for 4a and 4b respectively are considerably higher than those of obtained in 
the quenching studies (log KQ = 5.96 ± 0.1 and 5.88 ± 0.1). This finding refers to the 
existence of other binding sites of these two compounds on HSA besides site 1. Even 1b and 
2b show moderate interaction with HSA (see Fig. S7 in Supplementary Materials) that takes 
place most probably not at site 1, since no Trp quenching could be detected for these ligands. 
Log K = 4.67 ± 0.1 could be computed for 2b only. 
3.4. Starting structures of the HSA – coumarins complexes by molecular docking 
As mentioned previously, binding of ligands to HSA is extraordinarily eminent for the 
distribution and elimination of the drug as well as duration and intensity of its 
pharmacological or toxicological action. Molecular docking was conducted within subdomain 
IIA in Sudlow’s site 1 formed by six helices (Fig. 8a) as the most probably pocket for 7-O-
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arylpiperazinyl-4-methylcoumarins. The most favorable eight conformations of 1a – 4a and 
1b – 4b with the lowest docking energy were found in 30 independent runs. The inner wall of 
the pocket of site 1 is formed by hydrophilic side chains (Glu-153, Ser-192, Lys-195, Lys-
199, Arg-222, Arg-257, Ala-261, Ser-287, Ala-291, and Glu-292), and a hydrophobic region 
(formed by Phe-146, Phe-156, Phe-157, Trp-214, Leu-219, Leu-238, His-242, Leu-260, Ile-
264, Ile-290, and Ala-291) (see Figs. 8b and 8c). As shown in Fig. 8c coumarins are on the 
entrance of the site 1 of HSA and the molecular distance between the coumarin ring and the 
core of the benzene ring in Trp-214 residues is in the range from 7.06 – 13.89 Å. The defined 
starting locations of tested coumarin derivatives in HSA pocket are similar. Molecular 
dynamics simulations were made to better simulate the interactions of 1a – 4a and 1b – 4b 
with the rests of amino acids or water molecules and to get binding free enthalpy of the 
hypothetical complexes. 
3.5. Binding free enthalpy and interactions of tested coumarins with HSA 
MD simulations were made for each HSA - ligand complex in Sudlow site 1 as the pocket 
suggested for coumarin derivatives. The RMSD values between the ligand starting and the 
resulted average structures were low in all cases. The binding free enthalpy values for 1a – 4a 
and 1b – 4b calculated using the MM-PBSA method are presented in Table 5 together with 
the experimental values obtained using Gibbs’ isotherm and log KQ values (Gexp = -2.303 
RT log KQ). The experimental values were not obtained for compounds 1b and 2b (see 
Section 3.3), suggesting that these two compounds interact with HSA beside the site 1. The 
computational and experimental values of the free enthalpy differences are in the range of 
0.54 to 1.54 kcal/mol. The resulting differences may be due by two reasons: one that the X-
ray structure of the HSA from crystals even after MD simulation differs from that of the 
experimental aqueous conditions, and the second that the ligands do not interact effectively 
with the hypothetical pocket. The calculated strength of interactions with HSA decrease in the 
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sequence: 4a > 4b > 3a > 3b > 2a > 2b > 1a > 1b (-9.66 kcal mol-1 > -8.89 kcal mol-1 > -8.64 
kcal mol-1 > -8.45 kcal mol-1 > -7.84 kcal mol-1 > -7.75 kcal mol-1 > -7.69 kcal mol-1 > -6.36 
kcal mol-1, respectively). The MD resulting orientations of ligands are presented in Fig. 9 for 
compounds 1a – 4a with the propylene linker and in Fig. 10 for compounds 1b – 4b with the 
butylene linker. The coumarin rings of all tested compounds were similarly located within the 
hydrophobic binding pocket of HSA mainly surrounded by Leu-238, Leu-260, Ile-264, Ile-
290, and Ala-291, whereas the acetyl group at 8-position makes hydrogen bonds primarily 
with Lys-199, and His-242, Arg-257, and Ser-287. The rest of the molecule elements (alkyl 
chains, piperazine and benzene rings) were the deciding factors showcasing the differences in 
binding modes with HSA. The propylene linker adopts an extended conformation in the 
complexes of compounds 1a – 4a with benzene ring twisted only in compound 2a, while the 
butylene linker adopts a folded conformation in the complexes of compounds 1b – 4b. 
From the experimental studies of HSA fluorescence quenching, it is clear that majority of 
tested compounds (except 1b and 2b) are located next to the Trp-214 amino residue and show 
distinct differences in their binding ability. The MD simulation results showed that the 
location within the cavity of compounds 1a, 2a and 3a is almost the same, and molecules are 
predominantly surrounded by interior pocket residues Glu-153, Ser-192, Lys-195, Lys-199, 
and Glu-292 creating electrostatic interactions and hydrogen bonds. Compound 3a with the 2-
cyanophenyl substituent is highly solvated by water molecules present inside the pocket of 
site 1, which can play an important role in binding of 3a to HSA. The nearest distance of 
propoxy derivatives from Trp-214 residue is 7.06 Å for compound 4a (Table 5), so the MD 
studies showed the probability of strong quenching caused by 4a (Fig. 5a). The interaction 
between compound 4a and HSA is dominated by hydrophobic contacts with Phe-149, Phe-
156, Phe-157, Leu-238, Leu-260, Ile-290, and Ala-291, but there are also a number of specific 
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electrostatic interactions and hydrogen bonds. Especially the carbonyl group of the acetyl 
substituent at 8-position forms hydrogen bonds with Arg-257, Ala-261 and Ser-267. 
 The butoxy derivatives 1b – 4b are located in site 1 in such a way that the distances to 
Trp-214 residue are 13.89 Å for compound 1b, 10.13 Å for compound 2b, 8.94 Å for 
compound 3b and 7.59 Å for compound 4b. These calculated distances stand in good 
agreement with the quenching efficacy (see Fig. 5) of the compounds. The long distance close 
to 14 Å can be an answer for the practically unaltered fluorescence intensity for 1b and 2b 
upon binding to HSA (see Fig. S5 in Supplementary Materials). Compounds 1b, 2b and 4b 
are predicted to be accommodated in the HSA pocket in folded conformations, what is 
energetically unfavorable, and decreases the hydrophobic interactions with surrounding amino 
acids (Fig. 10). Compound 1b forms the hydrogen bonds with Ser-192, Lys-199 and His-242 
and creates electrostatic interaction with Lys-195 of HSA. The conformation of 3b differs 
from conformations 1b, 2b and 4b - the aromatic rings are located in opposed directions in 
relation to butyloxy linkers, and favorably interactions can be formed. Compound 3b creates 
electrostatic and hydrogen bond interactions with interior pocket residues Glu-153, Glu-292, 
Lys-199 and Ala-291, and hydrophobic interactions with Ala-191. 
4. Conclusions 
To sum up, in this work we have evaluated eight 8-acetyl-7-O-arylpiperazinyl-4-
methylcoumarin derivatives with strong binding ability towards 5-HT1A and 5-HT2A receptors 
aimed at gathering information about their potential application as orally administered 
antipsychotic agents. Theoretical values of drug likeness parameters as lipophilicity, 
topological polar surface area, and BBB permeation characteristics are in the regions for CNS 
drug candidates. The most promising compounds 4a and 4b have two Cl atoms at benzene 
ring. All compounds are partly protonated at pH 7.40, and their pKa values are in the range 
6.35 – 7.20. Studied coumarins can be metabolized by cytochrome P450 to aldehydes and 
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hydroxy derivatives. Tested coumarins are predicted as P-glycoprotein inhibitors what can 
increase their rate of uptake by the BBB. Unfortunately, the tested 8-acetyl-7-O-
arylpiperazinyl-4-methylcoumarin showed moderate-to-strong binding to human serum 
albumin. This phenomenon was studied experimentally and in silico in great detail. A 
logarithm of their experimental binding constants obtained from quenching measurements 
was in the range 5.25 - 5.96. Sudlow’s site 1 was proposed as the significant binding pocket 
inside HSA for compounds 1a, 2a, 3a and 3b, while for compounds 1b and 2b the existence 
of other binding site is postulated, and for compounds 4a and 4b, the commitment of two 
binding sites of HSA. Theoretical analysis of complexes in Sudlow site 1 showed that 
hydrophobic interaction is less probably for compounds 1b and 2b, and their distance to Trp-
214 is much longer than for other compounds. Theoretical and experimental results suggest 
that longer aliphatic linker between coumarin and piperazine moieties favored binding to 
HSA in other than Sudlow site 1 pocket. Overall the 8-acetyl-7-O-arylpiperazinyl-4-
methylcoumarin derivatives represent valuable lead compounds to be further studied in 
different preclinical assays as a possible treatment of diverse CNS diseases. 
Competing interest 
Authors disclose no potential conflicts of interest. 
Acknowledgments  
This work was partially supported by the Polish National Science Centre (NCN, 
project No. 2015/19/B/ST4/03743) and the Hungarian National Research, Development and 
Innovation Office-NKFI through project FK 124240, and the J. Bolyai Research Scholarship 
of the Hungarian Academy of Sciences (ÉAE). 
 
 26
*Correspondence authors: E-mail addresses: tzolek@wum.edu.pl (T. Żołek), 
dmaciejewska@wum.edu.pl (D. Maciejewska). 
 
Abbreviations 
AlkPhos, alkaline phosphatase; DFT, density functional theory; GGT, -glutamyl transferase; 
LDH, lactate dehydrogenase; LGA, Lamarckian genetic algorithm; logBB, logarithm of the 
brain/blood partition coefficient; MM-PBSA, molecular mechanics – Poisson Boltzmann 
surface area; MRTD, maximum recommended therapeutic dose; MWt, molecular weight; 
NVT, number of particles (N), system volume (V) and temperature (T) are constant/ 
conserved; NPT, number of particles (N), system pressure (P) and temperature (T) are 
constant/ conserved; P-gp, P-glycoprotein; RBP, blood-to-plasma concentration ratio; 
SGOT/AST, serum glutamate oxaloacetate transaminase; SGPT/ALT, serum glutamate 
pyruvate transaminase; TPSA, topological polar surface area; UGT, uridine 5’-diphosphate-
glucuronosyltransferases; %Unbnd, percent unbound to blood plasma proteins. 
  
 27
References 
[1] P. Morgan, P.H. Van der Graaf, J. Arrowsmith, D.E. Feltner, K.S. Drummond, C.D. 
Wegner, S.D.A. Street, Can the flow of medicines be improved? Fundamental 
pharmacokinetic and pharmacological principles toward improving Phase II survival, Drug 
Discov Today 17(9-10) (2012) 419-424. 
[2] W.M. Pardridge, Drug and gene targeting to the brain with molecular Trojan horses, Nat 
Rev Drug Discov 1(2) (2002) 131-9. 
[3] E. Neuwelt, N.J. Abbott, L. Abrey, W.A. Banks, B. Blakley, T. Davis, B. Engelhardt, P. 
Grammas, M. Nedergaard, J. Nutt, W. Pardridge, G.A. Rosenberg, Q. Smith, L.R. Drewes, 
Strategies to advance translational research into brain barriers, Lancet Neurol 7(1) (2008) 84-
96. 
[4] G. Bazzoni, E. Dejana, Endothelial cell-to-cell junctions: molecular organization and role 
in vascular homeostasis, Physiol Rev 84(3) (2004) 869-901. 
[5] N.J. Abbott, A.A.K. Patabendige, D.E.M. Dolman, S.R. Yusof, D.J. Begley, Structure and 
function of the blood-brain barrier, Neurobiol Dis 37(1) (2010) 13-25. 
[6] W.A. Banks, Characteristics of compounds that cross the blood-brain barrier, BMC 
Neurol 9 Suppl 1 (2009) S3. 
[7] M. Vastag, G.M. Keseru, Current in vitro and in silico models of blood-brain barrier 
penetration: a practical view, Curr Opin Drug Discov Devel 12(1) (2009) 115-24. 
[8] M.A. Musa, J.S. Cooperwood, M.O. Khan, A review of coumarin derivatives in 
pharmacotherapy of breast cancer, Curr Med Chem 15(26) (2008) 2664-79. 
[9] I. Kostova, Synthetic and natural coumarins as cytotoxic agents, Curr Med Chem 
Anticancer Agents 5(1) (2005) 29-46. 
[10] T. Żołek, D. Maciejewska, Theoretical evaluation of ADMET properties for coumarin 
derivatives as compounds with therapeutic potential, Eur J Pharm Scienc 109 (2017) 486-502. 
[11] K. Skalicka-Wozniak, I.E. Orhan, G.A. Cordell, S.M. Nabavi, B. Budzynska, Implication 
of coumarins towards central nervous system disorders, Pharmacol Res 103 (2016) 188-203. 
[12] Y. Chen, S. Wang, X. Xu, X. Liu, M. Yu, S. Zhao, S. Liu, Y. Qiu, T. Zhang, B.F. Liu, G. 
Zhang, Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives 
as potential multireceptor atypical antipsychotics, J Med Chem 56(11) (2013) 4671-90. 
[13] J.C. Gonzalez-Gomez, L. Santana, E. Uriarte, J. Brea, M. Villazon, M.I. Loza, M. De 
Luca, M.E. Rivas, G.Y. Montenegro, J.A. Fontenla, New arylpiperazine derivatives with high 
affinity for alpha1A, D2 and 5-HT2A receptors, Bioorg Med Chem Lett 13(2) (2003) 175-8. 
[14] T. Kanazawa, Brain delivery of small interfering ribonucleic acid and drugs through 
intranasal administration with nano-sized polymer micelles, Med Devices (Auckl) 8 (2015) 
57-64. 
[15] K.V. Sashidhara, A. Kumar, M. Kumar, S. Singh, M. Jain, M. Dikshit, Synthesis of novel 
3-carboxamide-benzocoumarin derivatives as orally active antithrombotic agents, Bioorg Med 
Chem Lett 21(23) (2011) 7034-40. 
[16] D.C. Carter, J.X. Ho, Structure of serum albumin, Adv Protein Chem 45 (1994) 153-203. 
[17] Y.Z. Zhang, B. Zhou, Y.X. Liu, C.X. Zhou, X.L. Ding, Y. Liu, Fluorescence study on the 
interaction of bovine serum albumin with p-aminoazobenzene, J Fluoresc 18(1) (2008) 109-
18. 
[18] K. Yamasaki, V.T. Chuang, T. Maruyama, M. Otagiri, Albumin-drug interaction and its 
clinical implication, Biochim Biophys Acta 1830(12) (2013) 5435-43. 
[19] Y.V. Il'ichev, J.L. Perry, J.D. Simon, Interaction of ochratoxin a with human serum 
albumin. Preferential binding of the dianion and pH effects, J. Phys. Che. B 106 (2002) 452-
459. 
 28
[20] K.J. Fehske, U. Schlafer, U. Wollert, W.E. Muller, Characterization of an important drug 
binding area on human serum albumin including the high-affinity binding sites of warfarin 
and azapropazone, Mol Pharmacol 21(2) (1982) 387-93. 
[21] I. Sjoholm, B. Ekman, A. Kober, I. Ljungstedt-Pahlman, B. Seiving, T. Sjodin, Binding 
of drugs to human serum albumin:XI. The specificity of three binding sites as studied with 
albumin immobilized in microparticles, Mol Pharmacol 16(3) (1979) 767-77. 
[22] A.M. Zaton, J.M. Ferrer, J.C. Ruiz de Gordoa, M.A. Marquinez, Binding of coumarins to 
site I of human serum albumin. Effect of the fatty acids, Chem Biol Interact 97(2) (1995) 169-
74. 
[23] T. Żolek, E.A. Enyedy, K. Ostrowska, V. Posa, D. Maciejewska, Drug likeness 
prediction of 5-hydroxy-substituted coumarins with high affinity to 5-HT1A and 5-HT2A 
receptors, Eur J Pharm Sci  (2018) 25-36. 
[24] A.M.L. Zaton, J.P. Villamor, Study of heterocycle rings binding to human serum 
albumin, Chem-Biol Interact 124(1) (2000) 1-11. 
[25] D. Li, B. Ji, H. Sun, Probing the binding of 8-Acetyl-7-hydroxycoumarin to human 
serum albumin by spectroscopic methods and molecular modeling, Spectrochim Acta A Mol 
Biomol Spectrosc 73(1) (2009) 35-40. 
[26] K. Ostrowska, K. Mlodzikowska, M. Gluch-Lutwin, A. Grybos, A. Siwek, Synthesis of a 
new series of aryl/heteroarylpiperazinyl derivatives of 8-acetyl-7-hydroxy-4-methylcoumarin 
with low nanomolar 5-HT1A affinities, Eur J Med Chem 137 (2017) 108-116. 
[27] Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2017, 
San Diego: Dassault Systèmes, 2016. 
[28] M.J. Frish, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, 
V.G. Zakrzewski, J.A.J. Montgomery, R.E. Stratmann, J.C. Burant, S. Dapprich, J.M. Millam, 
A.D. Daniels, K.N. Kudin, M.C. Strain, O. Farkas, J. Tomasi, V. Barone, M. Cossi, R. 
Cammi, B. Mennucci, C. Pomelli, C. Adamo, S. Clifford, J. Ochterski, G.A. Petersson, P.Y. 
Ayala, Q. Cui, K. Morokuma, D.K. Malick, A.D. Rabuck, K. Raghavachari, J.B. Foresman, J. 
Cioslowski, J.V. Ortiz, A.G. Baboul, B.B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. 
Komaromi, R. Gomperts, R.L. Martin, D.J. Fox, T. Keith, M.A. Al-Laham, C.Y. Peng, A. 
Nanayakkara, C. Gonzalez, M.P. Challacombe, P.M.W. Gill, B. Johnson, W. Chen, M.W. 
Wong, J.L. Andres, C. Gonzalez, M. Head-Gordon, E.S. Replogle, J.A. Pople, Gaussian, Inc., 
Pittsburgh, PA  (2009). 
[29] ADMET PredictorTM  Simulations Plus, Inc., Lancaster, California, USA. 
[30] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. 
Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor 
flexibility., J Comput Chem 30 (2009) 2785 - 2791. 
[31] B.R. Brooks, R.E. Bruccoleri, B.D. Olafson, D.J. States, S. Swaminathan, M. Karplus, 
Charmm - a program for macromolecular energy, minimization, and dynamics calculations., J 
Comput Chem 4 (1983) 187-217. 
[32] W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, M.L. Klein, Comparison 
of simple potential functions for simulating liquid water, J Chem Phys 79 (1983) 926-935. 
[33] L. Verlet, Computer experiments on classical fluids .I. Thermodynamical properties of 
Lennard-Jones molecules, Phys Rev 159 (1967) 98-103. 
[34] P.A. Kollman, I. Massova, C. Reyes, B. Kuhn, S. Huo, L. Chong, M. Lee, T. Lee, Y. 
Duan, W. Wang, O. Donini, P. Cieplak, J. Srinivasan, D.A. Case, T.E. Cheatham, Calculating 
structures and free energies of complex molecules: combining molecular mechanics and 
continuum models., Acc Chem Res 33 (2000) 889-897. 
[35] G.H. Beaven, S.H. Chen, A. d' Albis, W.B. Gratzer, A spectroscopic study of the 
haemin--human-serum-albumin system, Eur J Biochem 41(3) (1974) 539-46. 
 29
[36] L. Zékány, I. Nagypál, D.J.E. Leggett, Computational methods for the determination of 
formation constants, Plenum Press, New York  (1985) pp. 291-353. 
[37] O. Domotor, C.G. Hartinger, A.K. Bytzek, T. Kiss, B.K. Keppler, E.A. Enyedy, 
Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and 
KP1339 on human serum albumin via competition studies, J Biol Inorg Chem 18(1) (2013) 9-
17. 
[38] T. Sakaeda, N. Okamura, S. Nagata, T. Yagami, M. Horinouchi, K. Okumura, F. 
Yamashita, M. Hashida, Molecular and pharmacokinetic properties of 222 commercially 
available oral drugs in humans, Biol Pharm Bull 24(8) (2001) 935-40. 
[39] M.H. Abraham, F. Martins, R.C. Mitchell, C.J. Salter, Hydrogen bonding. 47. 
Characterization of the ethylene glycol-heptane partition system: hydrogen bond acidity and 
basicity of peptides, J Pharm Sci 88(2) (1999) 241-7. 
[40] T.T. Wager, R.Y. Chandrasekaran, X. Hou, M.D. Troutman, P.R. Verhoest, A. 
Villalobos, Y. Will, Defining desirable central nervous system drug space through the 
alignment of molecular properties, in vitro ADME, and safety attributes, ACS Chem Neurosci 
1(6) (2010) 420-34. 
[41] N.A. Meanwell, Improving drug candidates by design: a focus on physicochemical 
properties as a means of improving compound disposition and safety, Chem Res Toxicol 
24(9) (2011) 1420-56. 
[42] J. Kelder, P.D. Grootenhuis, D.M. Bayada, L.P. Delbressine, J.P. Ploemen, Polar 
molecular surface as a dominating determinant for oral absorption and brain penetration of 
drugs, Pharm Res 16(10) (1999) 1514-9. 
[43] H. van de Waterbeemd, G. Camenisch, G. Folkers, J.R. Chretien, O.A. Raevsky, 
Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-
bonding descriptors, J Drug Target 6(2) (1998) 151-65. 
[44] W.M. Pardridge, Drug transport across the blood-brain barrier, J Cereb Blood Flow 
Metab 32(11) (2012) 1959-72. 
[45] T.B. Fernandes, M.C.F. Segretti, M.C. Polli, R. Parise, Analysis of the Applicability and 
Use of Lipinski's Rule for Central Nervous System Drugs, Lett Drug Des Discov 13(10) 
(2016) 999-1006. 
[46] S.A. Hitchcock, Blood-brain barrier permeability considerations for CNS-targeted 
compound library design, Curr Opin Chem Biol 12(3) (2008) 318-23. 
[47] H. Pajouhesh, G.R. Lenz, Medicinal chemical properties of successful central nervous 
system drugs, NeuroRx 2(4) (2005) 541-53. 
[48] H. Fischer, R. Gottschlich, A. Seelig, Blood-brain barrier permeation: molecular 
parameters governing passive diffusion, J Membr Biol 165(3) (1998) 201-11. 
[49] T.J. Raub, B.S. Lutzke, P.K. Andrus, G.A. Sawada, B.A. Staton, Early preclinical 
evaluation of brain exposure in support of hit identification and lead optimization, Biotechnol 
Pharm Asp 4 (2006) 355. 
[50] J. Weiss, S.M. Dormann, M. Martin-Facklam, C.J. Kerpen, N. Ketabi-Kiyanvash, W.E. 
Haefeli, Inhibition of P-glycoprotein by newer antidepressants, J Pharmacol Exp Ther 305(1) 
(2003) 197-204. 
[51] F.E. O'Brien, G.M. Moloney, K.A. Scott, R.M. O'Connor, G. Clarke, T.G. Dinan, B.T. 
Griffin, J.F. Cryan, Chronic P-glycoprotein inhibition increases the brain concentration of 
escitalopram: potential implications for treating depression, Pharmacol Res Perspect 3(6) 
(2015) e00190. 
[52] B.N. Matto, Absorption and fluorescence spectra of coumarins, Transactions of the 
Faraday Society 52 (1956) 1184-1194. 
[53] T.J. Peters, All about albumin, biochemistry, genetics, and medical applications, 
Academic Press, New York (1996). 
 30
[54] G. Fanali, A. di Masi, V. Trezza, M. Marino, M. Fasano, P. Ascenzi, Human serum 
albumin: from bench to bedside, Mol Aspects Med 33(3) (2012) 209-90. 
[55] G. Sudlow, D.J. Birkett, D.N. Wade, Further characterization of specific drug binding 
sites on human serum albumin, Mol Pharmacol 12(6) (1976) 1052-61. 
[56] O. Domotor, T. Tuccinardi, D. Karcz, M. Walsh, B.S. Creaven, E.A. Enyedy, Interaction 
of anticancer reduced Schiff base coumarin derivatives with human serum albumin 
investigated by fluorescence quenching and molecular modeling, Bioorg Chem 52 (2014) 16-
23. 
[57] X.L. Ma, C. Chen, J. Yang, Predictive model of blood-brain barrier penetration of 
organic compounds, Acta Pharmacol Sin 26(4) (2005) 500-12. 
  
 31
O O
CH3
H3C O
ONH
N
F
 
1a 
O O
CH3
H3C O
O
NH
N
F
 
1b 
O O
CH3
H3C O
ONH
NO
H3C
 
2a 
O
H3C
O
O
H3C
O
NH
N
OH3C
 
2b 
O O
CH3
H3C O
ONH
N
CN
 
3a 
O O
CH3
H3C O
O
NH
N
CN
 
3b 
O O
CH3
H3C O
ONH
N
Cl
Cl
 
4a 
O O
CH3
H3C O
O
NH
N
Cl
Cl
 
4b 
 
Fig. 1. The chemical structure of tested coumarin derivatives 1a – 4a and 1b – 4b. 
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Fig. 2. pH-Dependent UV-vis spectra of 2a and at the upper side calculated individual molar 
spectra of the ligand species in the two protonation states L and HL+. (c = 19.6 µM; l = 2 cm; 
t = 25 °C; I = 0.10 M (KCl)). 
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Fig. 3. Measured (○) and fitted distribution coefficients (DpH) for 2a at different pH values. 
Fitted curves correspond to the model 1 where only the distribution of the neutral form is 
expected (dashed line), and to the model 2 where both L and HL+ forms may distribute 
between the polar and non-polar phases (solid line). Inset shows the initial part of the 
functions in the pH range from 2.0 to 6.0. (DpH values were determined in n-octanol/water 
system at the indicated pH values by traditional shake flask method; see details in the Section 
2.2.2) 
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Fig. 4. Fluorescence emission spectra of HSA ‒ 4a system. The grey dotted line shows the 
spectrum for 4a alone at 10 µM concentration. (cHSA = 1 mM; ccomp = 0 -10 mM; lEX = 295 
nm; t = 25 °C; pH = 7.40 (20 mM phosphate buffer); I = 0.1 M (KCl)). 
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Fig. 5. Measured quenching of the Trp fluorescence emission intensity of HSA as I/I0 (%) by 
the addition of the propyloxy derivatives (a): 1a (♦), 2a (●); 3a (▲); 4a (■), and butyloxy 
derivatives (b): 1b (♦), 2b (●); 3b (▲); 4b (■). Empty symbols correspond to the relative 
emission of the compounds alone. (cHSA = 1 mM; λEX = 295 nm; λEM = 340 nm; t = 25 °C; pH 
= 7.40 (20 mM phosphate buffer); I = 0.10 M (KCl)). 
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Fig. 6. Three-dimensional fluorescence spectra of HSA (a) compound 3a (b) and HSA ‒ 3a 
(1:11) system (c); peak intensities and wavelength coordinates (Intensity, [λEX, λEM expressed 
in nm]) are indicated in the figure (cHSA = 1 mM; ccomp = 11 mM; t = 25 °C; pH = 7.40 (20 mM 
phosphate buffer); I = 0.10 M (KCl)). 
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Fig. 7. Emission spectra of 3a upon addition of HSA. Inset shows the intensity changes at λEM 
= 410 nm. (ccomp = 2.8 mM; cHSA = 0-23 mM; λEX = 330 nm; t = 25 °C; pH = 7.40 (20 mM 
phosphate buffer); I = 0.10 M (KCl)). Spectra are corrected by the light scattering effect of 
HSA, see details in the Supplementary Materials, Fig S6. 
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(a) 
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Fig. 8. View of coumarin derivatives in site 1 of HSA. (a) Structure of HSA showing the 
subdomains and binding sites of compounds 1a – 4a and 1b – 4b. Compounds around the 
binding pocket are shown as spheres. (b) The hydrophobic and hydrophilic amino acid 
residues surrounding the ligands. Surface hydrophobicity was depicted by the shaded colors: 
brown – the hydrophobic and blue – lipophilic regions. (c) Superposition of compounds: 1a 
(green), 2a (blue), 3a (orange), 4a (red), 1b (dark green), 2b (dark blue), 3b (yellow) and 4b 
(pink). 
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Fig. 9. Structures of the 1a – HSA, 2a – HSA, 3a – HSA and 4a – HSA complexes, and 2D 
view of all HSA residues interacting with the ligands resulting from MD simulations (residues 
4a - HSA 
1a - HSA 
2a - HSA 
3a - HSA 
 40
involved in hydrogen bonding marked as green and cyan circles; in hydrophobic interactions 
marked as pink circle and electrostatic interactions marked as orange circle). 
  
 41
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Structures of the 1b – HSA, 2b – HSA, 3b – HSA and 4b – HSA complexes, and 2D 
view of all HSA residues interacting with the ligands resulting from MD simulations (residues 
1b - HSA 
2b - HSA 
4b - HSA 
3b - HSA 
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involved in hydrogen bonding marked as green and cyan circles; in hydrophobic interactions 
marked as pink circle and electrostatic interactions marked as orange circle). 
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Table 1 Theoretical values of topological polar surface area (TPSA), percentage of unbound 
drug to blood plasma proteins (%Unbnd), blood-to-plasma concentration ratio (RBP), BBB 
filter, blood-brain barrier partition coefficient (logBB), likelihood of the P-glycoprotein 
inhibition (P-gp) and predicted proton dissociation constants (pKa) for coumarins 1a – 4a and 
1b – 4b. 
Compound 
TPSA %Unbnd RBP BBB filter logBBa P-gp pKa 
Expected values 
(90Å2) (>10%) (<1) (high/ low)    
O O
CH 3
H 3C O
ON H
N
F
1a 
62.99 1.771 0.655 high 0.183 I 6.98 
O O
CH3
H3C O
ONH
NO
H3C
2a 
72.22 1.937 0.627 high -0.190 I 6.74 
O O
CH3
H3C O
ONH
N
CN
3a 
86.78 2.301 0.608 high -0.610 I 6.93 
O O
CH3
H3C O
ONH
N
Cl
Cl
4a 
62.99 0.865 0.667 high 0.257 I 6.99 
O O
CH3
H3C O
O
NH
N
F
1b 
62.99 2.065 0.648 high 0.282 I 7.39 
O
H3C
O
O
H3C
O
NH
N
OH3C
2b 
72.22 2.099 0.622 high -0.096 I 7.20 
O O
CH3
H3C O
O
NH
N
CN
3b 
86.78 2.347 0.604 high -0.543 I 7.14 
O O
CH3
H3C O
O
NH
N
Cl
Cl
4b 
62.99 0.997 0.660 high 0.368 I 7.41 
a According to the classification made by Ma et al. [57]: high absorption to CNS: logBB more than 0.3; middle 
absorption to CNS: logBB 0.3 – (-1.0); low absorption to CNS: logBB less than -1.0.  
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Table 2 Prediction of interactions with various isoforms of hepatic microsomal cytochromes 
CYP450 enzymes for coumarins 1a – 4a and 1b – 4b. 
Compound 
CYP 
mode of action 
1A2 2C9 2C19 2D6 3A4 
O O
C H3
H3C O
ONH
N
F
1a 
S I S I/S I/S 
O O
CH3
H3C O
ONH
NO
H3C
2a 
S I S I/S I/S 
O O
CH3
H3C O
ONH
N
CN
3a 
S I S I I/S 
O O
CH3
H3C O
ONH
N
Cl
Cl
4a 
S I S I/S I/S 
O O
CH3
H3C O
O
NH
N
F
1b 
S I S I/S I/S 
O
H3C
O
O
H3C
O
NH
N
OH3C
2b 
S I S I/S I/S 
O O
CH3
H3C O
O
NH
N
CN
3b 
S I S I I/S 
O O
CH3
H3C O
O
NH
N
Cl
Cl
4b 
S I S I/S I/S 
I – denotes inhibition of CYP isoforms; S – denotes substrate for CYP isoform. 
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Table 3 Predicted toxicity parameters for coumarins 1a – 4a and 1b – 4b: maximum 
recommended therapeutic dose MRTD, level of alkaline phosphatase (AlkPhos); level of -
glutamyl transferase (GGT), level of serum glutamate oxaloacetate transaminase (SGOT), 
level of serum glutamate pyruvate transaminase (SGPT), level of lactate dehydrogenase 
(LDH). 
Compound 
MRDT AlkPhos GGT LDH SGOT SGPT 
Expected values 
(>3.16 mg/kg/day)      
O O
CH3
H3C O
ONH
N
F
1a 
Below 3.16 NT NT NT NT NT 
O O
CH3
H3C O
ONH
NO
H3C
2a 
Above 3.16 NT NT NT NT NT 
O O
CH3
H3C O
ONH
N
C N
3a 
Below 3.16 NT NT NT NT NT 
O O
CH3
H3C O
ONH
N
Cl
Cl
4a 
Above 3.16 NT NT NT NT NT 
O O
CH3
H3C O
O
NH
N
F
1b 
Below 3.16 NT NT NT NT NT 
O
H3C
O
O
H3C
O
NH
N
OH3C
2b 
Above 3.16 NT NT NT NT NT 
O O
CH3
H3C O
O
NH
N
CN
3b 
Below 3.16 NT NT NT NT NT 
O O
CH3
H3C O
O
NH
N
Cl
Cl
4b 
Above 3.16 NT NT NT NT NT 
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Table 4 Proton dissociation constants (pKa) for coumarins 1a – 4a and 1b – 4b estimated from the pH-dependence of n-octanol/water 
distribution coefficient (DpH) values; distribution of the ligand species at pH 7.40 in water; partition coefficients (P) of the ligand species 
L and HL+ and distribution coefficient (D7.4) at pH 7.40 in n-octanol/water; absorption maximum (λmax) and molar absorbance (ε) of the 
HL+ form; lEM)max and relative fluorescence emission intensity values for the compounds at pH 7.4; conditional binding constants to 
HSA on site 1 (log KQ) (t = 25C, I = 0.10 M KCl). 
 1a 2a 3a 4a 1b 2b 3b 4b 
pKa UV-vis 6.95 ± 0.04 6.86 ± 0.03
a 6.90 ± 0.04 6.35 ± 0.08 7.20 ± 0.05 7.13 ± 0.04 7.15 ± 0.04 6.72b 
HL+7.40 (%) 26 22 24 8 39 35 36 17
b 
L7.40 (%) 74 78 76 92 61 65 64 83
b 
log PL 3.26 ± 0.01 2.95 ± 0.01 3.14 ± 0.02 3.5 ± 0.1 3.41 ± 0.03 3.08 ± 0.04 3.27 ± 0.05 3.65
b 
log PHL+ 0.84 ± 0.08 0.84 ± 0.06 0.61 ± 0.09 1.96 ± 0.06 0.97 ± 0.08 0.90 ± 0.04 0.80 ± 0.08  
log D7.40 3.11 2.80 2.99 3.35 3.26 2.93 3.12 3.52
b 
lmax / nm (e / M
-1cm-1) of HL+ 321(12400) 321(14100) 321(15500) 321(11600) 322(14100) 322(17100) 322(16700) 322(13900) 
lEM)max (nm) 422 424 405 424 423 424 397 408 
relative intensityc 0.29 0.31 0.64 0.29 0.41 0.46 1.00 0.54 
log KQ (HSA)
d 5.25 ± 0.1 5.33 ± 0.1 5.75 ± 0.1 5.96 ± 0.1 n.d n.d. 5.70 ± 0.1 5.88 ± 0.1 
KD
e mM mM mM mM   mM mM 
a pKa = 7.06 ± 0.01 determined by UV-vis spectrophotometric titrations; 
b predicted value based on the tendencies of the other derivatives; c 
Relative fluorescence intensities measured at emission maxima and at λ(EX) = 322 nm at pH 7.4; d Measured at pH 7.4 (20 mM phosphate buffer, 
0.1 M KCl); e KD = dissociation constant of the HSA adduct (KD = 1/ KQ)
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Table 5 Theoretical and experimental free enthalpy of binding to HSA, and average distance 
of ligand to tryptophan Trp-214 for coumarin derivatives. 
Compound 
Gbind 
(kcal mol-1) 
Gexp
a 
(kcal mol-1) 
r  
(Å) 
O O
CH3
H 3C O
ON H
N
F
1a 
-7.69 -7.15 8.94 
O O
CH3
H3C O
ONH
NO
H3C
2a 
-7.84 -7.26 8.18 
O O
CH3
H3 C O
ONH
N
CN
3a 
-8.64 -7.84 7.61 
O O
CH3
H3C O
ONH
N
Cl
Cl
4a 
-9.66 -8.12 7.06 
O O
CH3
H3C O
O
NH
N
F
1b 
-6.36 - 13.89 
O
H3C
O
O
H3C
O
NH
N
OH3C
2b 
-7.75 - 10.13 
O O
CH3
H3C O
O
NH
N
CN
3b 
-8.45 -7.77 8.94 
O O
CH3
H3C O
O
NH
N
Cl
Cl
4b 
-8.89 -8.01 7.59 
a Gexp = -2.303 RT log KQ 
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S-1. Computed drug likeness parameters 
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Fig. S1 Products of metabolism (Phase I) of 8-acetyl-7-hydroxy-4-methylcoumarin 
derivatives. 
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Table S1 Parameters joined with Lipinskis rule of five for coumarins 1a – 4a and 1b – 4b. 
Compound 
MWt log P log D HBD HBA 
Expected values 
(450 g/mol) (5) (4) (3) (7) 
O O
CH3
H3C O
ONH
N
F
1a 
438.502 4.023 3.843 0 6 
O O
CH3
H3C O
ONH
NO
H3C
2a 
450.538 3.844 3.718 0 7 
O O
CH3
H3C O
ONH
N
CN
3a 
445.521 3.408 3.322 0 7 
O O
CH3
H3C O
ONH
N
Cl
Cl
4a 
489.402 4.667 4.525 0 6 
O O
CH3
H3C O
O
NH
N
F
1b 
452.529 4.361 4.015 0 6 
O
H3C
O
O
H3C
O
NH
N
OH3C
2b 
464.565 4.181 3.928 0 7 
O O
CH3
H3C O
O
NH
N
CN
3b 
459.459 3.723 3.535 0 7 
O O
CH3
H3C O
O
NH
N
Cl
Cl
4b 
503.429 4.984 4.677 0 6 
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Table S2 Probability of metabolism by human uridine 5’-diphosphate-
glucuronosyltransferases (UGT) for coumarins 1a – 4a and 1b – 4b. 
Compound 
UGT 
1A1 1A3 1A4 1A6 1A8 1A9 1A10 2B7 2B15 
O O
CH3
H3C O
ONH
N
F
1a 
No No Yes No No No No No No 
O O
CH3
H3C O
ONH
NO
H3C
2a 
No No Yes No No No No No No 
O O
CH3
H3C O
ONH
N
CN
3a 
No No Yes No No No No No No 
O O
CH3
H3C O
ONH
N
Cl
Cl
4a 
No No Yes No No No No No No 
O O
CH3
H3C O
O
NH
N
F
1b 
No No Yes No No No No No No 
O
H3 C
O
O
H3C
O
NH
N
OH3C
2b 
No No Yes No No No No No No 
O O
CH3
H3C O
O
NH
N
CN
3b 
No No Yes No No No No No No 
O O
CH3
H3C O
O
NH
N
Cl
Cl
4b 
No No Yes No No No No No No 
 
 
 
 
 
 
 
S-2. Model selection of the lipophilicity measurements 
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Fig. S2 Two models of species distribution. 
Let suppose a charge neutral compound L that can be protonated evolving the 
positively charged HL+ form. Two cases are possible regarding the n-octanol/water partition 
of the two forms. In the first case (model 1) only the neutral form L distributes between the 
two phases, PHL+ is practically equal to zero. On the other hand, model 2 allows the diffusion 
of both forms into the non-polar (octanolic) phase, PHL+ > 0. Namely, the knowledge of PHL+ 
decides which model to use. The proton dissociation constant (Ka) can be calculated from the 
measured pH dependent distribution coefficients (DpH) based on the proper distribution model 
presented in Fig. S2. 
  
Laq +  H
+ ⇌ HL+aq
Loct ⇌ HL
+
oct
Ka
?
PL0 PHL+aqueous phase
n-octanol phase
Laq +  H
+ ⇌ HL+aq
Loct
Ka
PL0
model 1 model 2
Ka =                   ; 
[Laq] [H
+] 
[HL+aq]
PL0 = 
[Loct] 
[Laq]
PHL+ = 
[HL+oct] 
[HL+aq]
 Ka ;    
DpH =                             
[Loct] + [HL
+
oct] 
[Laq] + [HL
+
aq] 
 PL0 ;   
Ka =  
DpH =                             
[Loct]  
[Laq] + [HL
+
aq] 
DpH =                             
PL0
1 + ([H+] / Ka)
[H+] 
(PL0 / DpH) – 1
Ka =  
DpH =                             
PL0 + PHL+ × ([H
+] / Ka)
1 + ([H+] / Ka)
(PHL+ – DpH) × [H
+] 
DpH – PL0
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S-3. Evaluation of pKa values 
The linear functions between the adequate pKa, log D7.4 and log PL pairs of the two-ligand 
series were observed when the exchange of the butylene linker between the coumarin and 
piperazine moieties to propylene linker was made (Fig. S3). 
 
Fig. S3 Tendencies between the pKa (a) log D7.4 (b) log PL (c) and log PHL (d) values of the 
propyloxy and butyloxy derivatives (♦), and extrapolated constants for 4b (▲). The values of 
log PHL do not show linear dependence; therefore, constant for 4b was not predicted. 
This phenomenon helped us to predict these constants for 4b (Fig. S2), which was found to be 
fairly insoluble in water at pH > 6.5. 
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S-4. Spectrofluorometric studies of interaction with HSA 
Spectrofluorometric properties of HSA-tested coumarins systems are illustrates in Figs. S4 – 
S7.  
 
Fig. S4 Time dependent fluorescence intensity of HSA upon addition of 5 eq. 1a. (cHSA = 1 
mM; ccomp = 5 mM; lEX = 295 nm; lEM = 340 nm; t = 25 °C; pH = 7.40 (20 mM phosphate 
buffer); I = 0.10 M (KCl)). 
 
 
Fig. S5 Fluorescence emission spectra of HSA ‒ 1b system. The grey dotted line shows the 
spectrum for 3b alone at 26 µM concentration. (cHSA = 1 mM; ccomp = 0-26 mM; lEX = 295 nm; 
t = 25 °C; pH = 7.40 (20 mM phosphate buffer); I = 0.10 M (KCl)). 
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Fig. S6 Emission spectra of 4a upon addition of HSA without correction by the light 
scattering effect of HSA (a); light scattering effect of HSA (b) and corrected emission spectra 
of 4a upon addition of HSA (c). (ccomp = 2.5 mM; cHSA = 0-15 mM; λEX = 330 nm; t = 25 °C; 
pH = 7.40 (20 mM phosphate buffer); I = 0.10 M (KCl)). 
 
 
Fig. S7 Normalized intrinsic emission of compounds 3a (▲); 4a (■); 1b (♦); 2b (●); 4b (■) 
and at λEM(max) upon addition of increasing amounts of HSA (ccomp = 2.4 - 3.3 mM; λEX = 
330 nm, λEM = see λEM(max) values in Table 4; t = 25 °C; pH = 7.40 (20 mM phosphate 
buffer); I = 0.10 M (KCl)). 
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